Latest News
Connected Thinking
Leading Voices
Latest News
For Women With Heavily-Treated Triple-Negative or HR+, HER2- Metastatic Breast Cancer, Padvec Shows Some Anti-Tumor Activity
There may be another new treatment option for women living with metastatic triple negative breast cancer. A promising new study presented at this year’s American Society of Clinical Oncology (ASCO) conference indicated that Enfortumab vedotin (brand name Padcev) may help women who haven’t responded to standard treatments. However, while the drug showed anti-tumor activity in […]
Learn MoreRytelo Gains FDA Approval for Lower-Risk Myelodysplastic Syndrome: Reducing Need For Blood Transfusions & Improving Quality of Life
There’s some wonderful news for people living with myelodysplastic syndrome (MDS), a rare type of blood cancer: the U.S. Food and Drug Administration (FDA) has recently approved a new treatment option that reduces the need for regular blood transfusions. Over 70% of patients with MDS, are classified as having lower-risk disease, and the majority of these […]
Learn MoreImfinzi Improves Overall & Progression-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer
Results from the phase III ADRIATIC trial, presented at this year’s American Society of Clinical Oncology (ASCO) conference, indicated that durvalumab (brand name Imfinzi) improved overall survival (OS) and progression-free survival (PFS) for patients with limited-stage small cell lung cancer (LS-SCLC). The trial demonstrated that Imfinzi had a statistically significant and clinically meaningful improvement in […]
Learn MoreNATALEE Trial Supports Use of Kisqali with HR+/HER2- Early-Stage Breast Cancer at Increased Risk of Recurrence
Research presented at this year’s American Society of Clinical Oncology (ASCO) conference indicated that ribociclib (brand name: Kisqali) can help reduce the risk of recurrence after treatment for patients with HR+/HER2- breast cancer with a high or medium risk of cancer returning. “More than 1 in 3 patients diagnosed with early-stage breast cancer, regardless of […]
Learn MoreUnprecedented Progression-Free Survival for ALK-Positive Non-Small Cell Lung Cancer Using Lorbrena — What the New Research Means for Patients
The results of the 5-year follow-up to the CROWN study have shown the promise of using the third-generation tyronise kinase inhibitor (TKI) lorlantinib (Lorbrena) for patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Study authors say it provided the longest progression-free survival (PFS) that has ever been reported in advanced lung […]
Learn MoreImmunohistochemical (IHC) Testing Drives Tailored Therapies for HER2-Positive Cancers
IHC testing is now vital for cancer care, identifying tumor antigens that can help guide decisions about targeted treatments like ADCs.
Learn MoreNew ASCO Guidelines Offer A Practice-Changing Approach For PIK3CA/AKT1/PTEN Metastatic Breast Cancer
ASCO Rapid Recommendation Update: Combining capivasertib with fulvestrant enhances PFS in metastatic breast cancer, ushering in personalized treatment options.
Learn MoreAn Evidence-Based Approach to Discussing Clinical Trials WIth Your Patients
A physician checklist can help ease the difficulty of discussing clinical trial participation with patients who are not responding to current treatment.
Learn More